The new Syrian government in Damascus sent a convoy of vehicles from the General Security Department to Afrin, a historically Kurdish city and district in northwest Syria. In 2018, Turkey launched a ...

ERBIL, Kurdistan Region - Security forces affiliated with the new leadership in Damascus briefly visited Afrin on Thursday and received a warm welcome from locals, including Kurds who raised the ...

ERBIL, Kurdistan Region - Four young Kurdish men were arrested in Afrin on Friday, a day after they raised the Kurdistan flag during a spontaneous reception for security forces affiliated with the ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

OKAY, HONEY, COME SIT HERE. TODAY, JOE IS TESTING SOMETHING NEW. A MEDICATION CALLED FOR INSIDE THIS NASAL SPRAY. ONE, TWO. THREE. JOE IS THE FIRST PATIENT WITH ALZHEIMER’S TO TRY THIS DRUG.

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monotherapy for adults with major depressive ...